BCM
CODX

Bayesian Capital Management’s Co-Diagnostics CODX Stock Holding History

Bayesian Capital Management’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-520
Closed -$212K – 484
2020
Q3 		$212K Buy
+520
New +$267K 0.05% 431

Other funds holding CODX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Bayesian Capital Management's CODX Position: Q4 2020 in Review

Bayesian Capital Management sold out of Co-Diagnostics (CODX) in Q4 2020, closing a stake of 520 shares — an estimated $212K sold.

Bayesian Capital Management first reported a position in CODX in Q3 2020 and held it in 1 quarter. The position peaked at $212K in Q3 2020. 83 funds tracked by Wall St. Rank hold CODX as of Q4 2020.

  • Bayesian Capital Management reported no remaining Co-Diagnostics position as of Q4 2020 after selling out during the quarter.
  • Bayesian Capital Management sold 520 Co-Diagnostics shares in Q4 2020, an estimated $212K.
  • Bayesian Capital Management first reported a position in Co-Diagnostics in Q3 2020 and held it in 1 quarter.
  • Bayesian Capital Management's Co-Diagnostics position peaked at $212K in Q3 2020.
  • 83 funds tracked by Wall St. Rank held Co-Diagnostics as of Q4 2020.

Based on Bayesian Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.